Articles tagged "HLA antibodies"

2021 American Transplant Congress
Donor-specific Anti-HLA Alloantibody in Kidney Transplant Recipients with COVID-19 Exhibit a Different Immunoglobulin Class and Subclass Profile When Compared to Anti-SARS-CoV-2 Antibodies
A. Girnita¹, L. Wang¹, M. Fernandez-Vina¹, E. Woodle², P. Ahearn¹, T. Yalamarti¹, M. Menon³, Y. Azzi⁴, M. Melcher¹, R. Bray⁵, H. Gebel⁵, E. Akalin⁴, P. Cravedi³, J. S. Maltzman¹
¹Stanford University, Palo Alto, CA, ²University of Cincinnati, Cincinnati, OH, ³Icahn School of Medicine, NYC, NY, ⁴Einstein School of Medicine, NYC, NY, ⁵Emory University, Atlanta, GA
*Purpose: Both anti-HLA and anti-SARS-CoV-2 antibodies target protein antigens. The aim of the present study was to compare the class and subclass profile of such…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
2021 American Transplant Congress
The Impact of Maintenance Immunosuppression Withdrawal on Sensitization Status After Renal Graft Failure
R. Hod Dvorai, A. Almonte, C. Hubbell, M. Laftavi, R. Shahbazov, R. Saidi, O. Pankewycz, J. Leggat, M. Hanlon, B. Gallay
SUNY Upstate Medical University, Syracuse, NY
*Purpose: Maintaining immunosuppression (IS) following failed renal transplant may lead to increased risk for infections and malignancies; on the other hand, withdrawal can lead to…
2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²
¹MedStar Georgetown University Hospital, Washington, DC, ²Temple University Hospital, Philadelphia, PA
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…
2021 American Transplant Congress
Outcomes of HLA Antibody Surveillance Protocol in Heart Transplant Patients – A Single-Center Retrospective Analysis
S. S. Patlolla, V. Bhattad, S. McKean, M. Askar, S. Hall
Baylor University Medical Center, Dallas, TX
*Purpose: Post-transplant care is multifaceted with protocols to provide oversight and maintain the standard of care. While institutional protocols for post-transplant HLA antibody surveillance after…
2021 American Transplant Congress
Association Between HLA Class II and TLR4 Regulates HLA-II Stimulated P-selectin Expression and Monocyte Capture to Endothelial Cells
Y. Jin, J. Nevarez-Mejia, E. F. Reed
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Antibody-mediated rejection (AMR) is a major obstacle for long-term allograft survival. Donor specific HLA antibodies (DSA) contribute to the process of AMR by binding…
2021 American Transplant Congress
Calcineurin Inhibitor Dose and Selection, Not Antiproliferatives or Steroids, Influence Development of DSA One Year Post-kidney Transplant
M. Henderson¹, G. Morris², L. Awdishu¹, K. Fabbri¹, M. Shah³, A. Khan³, J. Kerr¹
¹Pharmacy, University of California San Diego Health, San Diego, CA, ²Pathology, University of California San Diego Health, San Diego, CA, ³Nephrology, University of California San Diego Health, San Diego, CA
*Purpose: Allograft rejection is a serious complication in kidney transplantation (KT). Despite advances in immunosuppression, acute rejection remains a concern in the first year of…
2021 American Transplant Congress
Are All DSA’s the Same? Are We Ready for Precision Medicine in Pediatric LT?
S. E. Shin¹, M. Lee¹, N. Yazigi², K. Khan², S. Kaufman², J. Ahn³, O. Timofeeva⁴, U. Ekong²
¹Georgetown University School of Medicine, Washington, DC, ²Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC, ³Biostatistics, Bioinformatics, & Biomathematics, Georgetown University, Washington, DC, ⁴Histocompatibility Laboratory, Dept. of Pathology & Laboratory Medicine, Georgetown University, Washington, DC
*Purpose: Donor-specific antibodies (DSA) play an uncertain role in rejection after liver transplantation (LT). We hypothesized that evaluation of epitope differences in HLA-DR/DQ mismatching can…
2021 American Transplant Congress
Sharp Anti-HLA Antibody Development Due to Concomitant Graft Nephrectomy and Immunosuppression Withdrawal After Early Graft Loss
R. Valero¹, A. Aguilera¹, E. Rodrigo¹, D. San Segundo², M. Lopez-Hoyos², J. Ruiz¹
¹Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Inmunología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
*Purpose: The number of patients awaiting for retransplantation has been progressively increasing. The presence of anti-HLA antibodies can significantly lengthen the waiting time, limiting the…
2021 American Transplant Congress
Investigating the HLA Alloimmune Background of the Histological Changes Suggestive of Antibody-mediated Injury in the Absence of Donor-specific Anti-HLA Antibodies
A. Senev, M. Naesens
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: The histology of antibody-mediated rejection is observed frequently after kidney transplantation, but a significant percentage of the patients do not have detectable donor-specific HLA…

« Previous Page
1
…
4
5
6
7
8
…
47
Next Page »